Honorable John Carona, Chair, Senate Committee on Business & Commerce
FROM:
Ursula Parks, Director, Legislative Budget Board
IN RE:
SB992 by Taylor (Relating to misrepresentations in connection with certain drug testing devices or equipment; providing penalties.), As Introduced
No significant fiscal implication to the State is anticipated.
The bill would amend the Business and Commerce Code to prohibit a manufacturer or seller of drug testing equipment from representing that the equipment is capable of drug testing unless it has been approved by the United States Food and Drug Administration. The Office of the Attorney General indicates that any additional costs associated with the bill could be absorbed within existing resources.
Local Government Impact
The bill would establish a violation of the provision of the bill as a new Class C misdemeanor. A Class C misdemeanor is punishable by a fine of not more than $500. Costs associated with enforcement and prosecution could likely be absorbed within existing resources. New revenue from fines imposed and collected is not anticipated to have a significant fiscal impact.